These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36641478)

  • 1. Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program.
    Reed MK; Smith KR; Ciocco F; Hass RW; Cox AL; Kelly EL; Weinstein LC
    Subst Abuse Treat Prev Policy; 2023 Jan; 18(1):4. PubMed ID: 36641478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings.
    Hooker SA; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
    J Subst Abuse Treat; 2022 Oct; 141():108804. PubMed ID: 35643586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication for opioid use disorder in the Arab World: A systematic review.
    Alawa J; Muhammad M; Kazemitabar M; Bromberg DJ; Garcia D; Khoshnood K; Ghandour L
    Int J Drug Policy; 2022 Apr; 102():103617. PubMed ID: 35182841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
    Andraka-Christou B; Totaram R; Randall-Kosich O
    Subst Abus; 2022; 43(1):415-424. PubMed ID: 34214400
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
    Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
    Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
    [No Abstract]   [Full Text] [Related]  

  • 9. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
    Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
    Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
    Harrington C; Bailey A; Delorme E; Hano S; Evans EA
    Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
    [No Abstract]   [Full Text] [Related]  

  • 12. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
    Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
    J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery capital among people receiving treatment for opioid use disorder with buprenorphine.
    Parlier-Ahmad AB; Terplan M; Svikis DS; Ellis L; Martin CE
    Harm Reduct J; 2021 Oct; 18(1):103. PubMed ID: 34645477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total cost of care associated with opioid use disorder treatment.
    Toseef MU; Durfee J; Podewils LJ; Blum J; McEwen D; Hanratty R; Everhart R
    Prev Med; 2023 Jan; 166():107345. PubMed ID: 36370891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial.
    Thompson RG; Bollinger M; Mancino MJ; Hasin D; Han X; Bush KA; Kilts CD; James GA
    Trials; 2023 Apr; 24(1):255. PubMed ID: 37016394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.